LBCL: Bispecific Antibodies Fare Less Well in Real-World Analysis

In the real world, treating relapsed/refractory large B-cell lymphoma with epcoritamab and glofitamab leads to poorer outcomes than in clinical trials.
Medscape Medical News

source https://www.medscape.com/viewarticle/lbcl-bispecific-antibodies-fare-less-well-real-world-2024a1000mlg?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost